Transitioning from mavacamten to aficamten in obstructive HCM
Official title: Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
Run by Oregon Health and Science University · NCT07600177 · Data updated 2026-11-12
This study tests whether switching from mavacamten to aficamten is feasible and safe for people with obstructive hypertrophic cardiomyopathy who are already on mavacamten.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Oregon Health and Science University Academic / other |
| Locations | 2 sites (Kansas City, Missouri and 1 other locations) |
| Status | Recruiting |
| Started | May 5, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | March 15, 2027 |
| Registry record updated | May 20, 2026 |
| Trial ID | NCT07600177 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with obstructive HCM, on mavacamten, with LVOT obstruction ≥50 mmHg and LVEF ≥55% on mavacamten, able to provide informed consent.
✕Probably not a fit
Patients with low LVEF, significant aortic/sub-aortic obstruction, alternative causes of hypertrophy, or active coronary disease may not benefit from transition.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a two-center, investigator-initiated interventional study evaluating a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy. The trial will look at feasibility, safety, and preliminary efficacy after the switch, in participants with resting or Valsalva LVOT obstruction ≥ 50 mmHg and preserved LVEF while on mavacamten. Eligible participants must have LVEF ≥55% on mavacamten, and must consent to study procedures. Exclusion criteria include severe valvular disease, other causes of hypertrophy, low ejection fraction, certain atrial fibrillation conditions, or significant coronary disease.
Why it matters
Potential benefit: If successful, patients may experience improved control of obstruction and symptoms after the switch, with guidance on transitioning therapy.
How similar studies have gone: Previous approaches in CMIs have shown feasibility with careful monitoring; this exact transition approach is being evaluated in this two-center setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Documented history of oHCM with documented resting and/or Valsalva LVOT obstruction ≥ 50 mmHg who are currently receiving mavacamten commercially. * Echo-derived LVEF ≥55% on mavacamten at the time of enrollment. * Patient willing to consent for the study and undergo the study procedures. Exclusion Criteria: * Severe aortic stenosis or sub-aortic obstruction * Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM (eg, Noonan syndrome, Fabry disease, amyloidosis). * History of LVEF \<30%. * Paroxysmal atrial fibrillation (AF) with documented episode within 3 months. * Atrial fibrillation (paroxysmal or permanent) not on systemic anticoagulation. * Documented history of current obstructive coronary artery disease (\> 70% stenosis in one or more epicardial coronary arteries) or documented history of myocardial infarction.
Where it's running
-
Oregon Health & Science University
Portland, Oregon, United States Recruiting -
St. Luke's Hospital - Mid America Heart Institute
Kansas City, Missouri, United States Not yet recruiting
Study contacts
- Study coordinator: Ahmad Masri
- Email: masria@ohsu.edu
- Phone: 503-494-7551
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
68Ga-NI-FAPI-04 PET/CT imaging to detect fibroblast activation in cancer, fibrotic, and heart diseases
This test will see if an injected PET tracer called 68Ga-NI-FAPI-04 can better show fibroblast activation in people with tumors, pulmonary fibrosis, certain autoimmune vascular diseases, hypertrophic cardiomyopathy, or other cardiovascular conditions.
-
Understanding why AF happens and is harder to treat in hypertrophic cardiomyopathy
We’re testing how heart electrical signals and advanced imaging relate to atrial fibrillation in people with hypertrophic cardiomyopathy to see if treatments can be improved.
-
UK multicentre hypertrophic cardiomyopathy registry
This project collects health information from adults with hypertrophic cardiomyopathy across UK NHS hospitals to see which treatments and tests work best for different patients.
-
Multimodal analysis of heart biopsy samples
This project will take one extra small heart biopsy during a clinically needed procedure to test whether detailed molecular and immune analyses can find disease-specific signatures in adults with cardiomyopathies, myocarditis, cardiac amyloidosis, or after heart transplant.
-
T1 mapping to characterize heart tissue in common heart diseases
This project tests whether T1 mapping MRI scans, including dye-free native T1, can define normal and disease-specific heart tissue values for adults with various heart conditions.
-
Natural history of RASopathy-associated cardiomyopathy in infants and children
This project collects clinical and genetic records from infants and children with genetically confirmed RASopathy-associated hypertrophic cardiomyopathy to create a comparison dataset for future treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.